Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferric carboxymaltose + Tranexamic acid
- Development stage
- Phase 3
- Lead developer
- American Regent
- Modality
- Device-based Delivery → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Ferric carboxymaltose + tranexamic acid is a combination therapy used perioperatively to reduce transfusion rates in surgical patients. This combination addresses both iron deficiency anemia and excessive bleeding during surgery. Ferric carboxymaltose replenishes iron stores to improve hemoglobin levels, while tranexamic acid prevents excessive bleeding by inhibiting the breakdown of blood clots. The TRANAFER-Study is specifically investigating this combination in gynecological carcinoma surgery[1][2].
02
Targets
PLG (Plasminogen)Iron metabolism (Iron metabolism family)
Beyond the preview
Go deeper on Ferric carboxymaltose + Tranexamic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ferric carboxymaltose + Tranexamic acid.